Characterization of ERBB2 alterations in non-small cell lung cancer.
Vijendra K. Singh(Wayne State University), Misako Nagasaka(University of California, Irvine), Hossein Borghaei(Fox Chase Cancer Center), Luis E. Raez(Florida International University), Hirva Mamdani(Wayne State University), Rebecca Feldman(Caris Life Sciences (United States)), Ari M. Vanderwalde(West Cancer Center), Stephen V. Liu(Georgetown University), Alexander I. Spira(Virginia Cancer Specialists), Sachin Gopalkrishna Pai(USA Mitchell Cancer Institute), Edward S. Kim(The University of Texas MD Anderson Cancer Center), Joanne Xiu(Caris Life Sciences (United States)), Chukwuemeka Ikpeazu(Sylvester Comprehensive Cancer Center), Chul Kim(Georgetown University), Gerold Bepler(Moffitt Cancer Center), Antoinette J. Wozniak(Wayne State University), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute)
Cited by 4
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k